X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Future Biotech Platforms Likely To Depend Primarily On Urine

Content Team by Content Team
13th December 2022
in News, Research & Development

A mechanism that employs urea to begin the manufacturing of proteins in the massive amounts required by the biotech industry has been developed by researchers at the Universities of Birmingham and Aston.

Typically, in this procedure, little DNA fragments are added to bacteria like E.coli to induce them to overproduce particular proteins. It was initially developed in the 1970s and is now a well-known technology. However, inducer molecules, which can be expensive and frequently require special management, like refrigeration—typically cause overproduction.

The researchers have created a process that is less complicated, more affordable, and employs components that are readily available by substituting urea.

The scientists looked at both refined urea and the urea included in typical garden fertilisers in a recent study that was published in the journal New Biotechnology. They demonstrated that any source could produce results that were comparable.

Their objective is to make this technology accessible to biotech companies that want to investigate how to maximise their operations while also keeping their costs down, according to co-author and professor Steve Busby of the University of Birmingham’s School of Biosciences.

The scientists also demonstrated that by adjusting the doses used, it was feasible to precisely control the levels of protein induced by the urea molecule. To prevent hurting or wearing out the host microorganisms, it’s crucial to do this. They discovered it was possible to maximise output to levels comparable to those generated with medium-strength promoters, which are currently the norm in the biotech sector.

The research expands on previous work in which the scientists showed that nitrate, a readily available, affordable, and stable inorganic ion, may also be employed as a trigger. Since nitrate is frequently included in many commercial fertilisers and even some garden fertilisers, it is constantly accessible, even in places where other types of promoter chemicals would not be.

The School of Biosciences’ Dr. Joanne Hothersall, who is a co-author on the paper, said that both urea and nitrate will become much more easily accessible and easier to use in regions where infrastructure prevents access, for example when sustaining a cold supply chain is difficult. They anticipate that these novel methodologies will present fresh research opportunities for the biotech sector.

The Biotechnology and Biological Sciences Research Council, a division of UK research and innovation, provided funding for the study.

Previous Post

NICE Methodology Raises Concerns For Kidney Research UK

Next Post

Canadian And US Developers To Test Psychedelic Drugs In UK

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post

Canadian And US Developers To Test Psychedelic Drugs In UK

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In